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Abstract
Preparations of the root bark of Tabernanthe iboga have long been used in Central and West African traditional 
medicine to combat fatigue, as a neuro-stimulant in rituals, and for treatment of diabetes. The principal alkaloid 
of T. iboga, ibogaine, has attracted attention in many countries around the world for providing relief for opioid 
craving in drug addicts. Using a plant metabolomics approach, we detected five phenolic compounds, including 
3-O-caffeoylquinic acid, and 30 alkaloids, seven of which were previously reported from T. iboga root bark. Fol-
lowing a report that iboga extracts contain insulinotropic agents, we aimed to determine the potential alleviating 
effects of the water extract of iboga root bark on high-fat diet (HFD)-induced hyperglycemia as well as its effects 
on cognitive function in male C57BL/6J mice. Feeding a HFD to mice for 10 weeks produced manifestations of 
metabolic syndrome such as increased body weight and increased plasma levels of glucose, triacylglycerols, total 
cholesterol, LDL-cholesterol, insulin, leptin, and pro-inflammatory mediators (IL-6, MCP-1, ICAM-1), as compared 
to mice fed a low-fat diet (LFD). Supplementation of HFD with iboga extract at ibogaine doses of 0.83 (low) and 
2.07 (high) mg/kg/day did not improve these HFD-induced metabolic effects except for a reduction of plasma 
MCP-1 in the low dose group, indicative of an anti-inflammatory effect. When the HFD mice were tested in the 
water maze, the high-dose iboga extract caused hippocampus-dependent impairments in spatial learning and 
memory, as compared to mice receiving only a HFD.
Keywords: Alkaloids; 3-O-caffeoylquinic acid; Cognitive function; Diabetes; Ibogaine.
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1. Introduction
In traditional medicine practiced in Central and West Africa, in-
cluding Gabon, preparations of the root bark of Tabernanthe iboga 
(Apocynaceae) have been used for their hallucinogenic, neuro-
stimulant and anti-fatigue properties (Goutarel et al., 1993). Tradi-
tional healers in the province of Estuaire (Gabon) use the air-dried 
root bark or its maceration for treatment of diabetes (Souza et al., 
2011). Mechanistic studies of iboga extracts suggest a potential 
use for management of diabetes mellitus (Souza et al., 2011; Bad-
ing-Taika et al., 2018), which represents one of the most prevalent 
metabolic disorders resulting from defects in insulin secretion, in-
sulin action, or both. This metabolic disorder leads to microvascu-
lar (retinopathy, neuropathy and nephropathy) and macrovascular 
(heart attack, stroke and peripheral vascular disease) complica-
tions (Umar et al., 2010). Worldwide, the number of individuals 
with diabetes is increasing due to population growth, and it is ex-
pected that about 366 million people are likely to have developed 
diabetes by the year 2030 (Wild et al., 2004). Diabetes mellitus is 
classified into two major types. Type 1 diabetes (previously known 
as insulin-dependent, juvenile or childhood-onset) is characterized 
by deficient insulin production that is not preventable and requires 
insulin injection. Type 2 diabetes (formerly called non-insulin-de-
pendent or adult-onset) results from the body’s ineffective use of 
insulin and is largely the result of excess body weight and physical 
inactivity. Type 2 diabetes is the more prevalent form and is man-
ageable by anti-diabetic drugs and by changes in life style such 
as exercise, diet, and maintaining a healthy body weight. How-
ever, many of the various drugs prescribed for type 2 diabetes have 
significant risks of adverse effects. For instance, the anti-diabetic 
thiazolidinediones (glitazones) promote de novo lipogenesis and 
can exert long-term adverse side effects including increased body 
weight and cardiovascular toxicity (Zito, 2013). A meta-analysis of 
42 trials linked rosiglitazone (Avandia®) to a 43% increased risk 
of heart attack (p = 0.03) (Nissen and Wolski, 2007; Nissen, 2010). 
These findings strongly underscore the need for safer alternative 
intervention agents. Several bioactives of plant origin exhibit anti-
diabetic activity or insulin mimetic activity. They include poly-
phenols, tannins, alkaloids, carbohydrates, terpenoids, coumarins, 
steroids and flavonoids (Atta Ur and Zaman, 1989; Firdous, 2014; 
Patel et al, 2012; Bading-Taika et al., 2018).
The root bark of T. iboga and its preparations are used in Gabo-
nese traditional medicine combating fatigue, hunger, and AIDS in 
Central and West Africa (Goutarel et al., 1993; Souza et al., 2011) 
but their active principles are not fully identified or characterized. 
Aqueous extracts of T. iboga contain insulinotropic compounds 
that stimulate insulin secretion in rat pancreatic islets of Langer-
hans by blocking the ATP-sensitive K+ channels, thereby causing 
calcium influx through voltage-sensitive Ca2+ channels (Souza et 
al., 2011), similar to the actions of sulfonylureas, a class of main-
stream type 2 diabetic drugs. Moreover, ibogaine, the principal al-
kaloid of T. iboga, acutely increases respiratory activity and energy 
(ATP) expenditure and it induces an antioxidant stress response in 
rats (Paškulin et al., 2012), all of which would be beneficial in the 
prevention or treatment of type 2 diabetes. Ibogaine is a psychoac-
tive alkaloid used worldwide in the treatment of drug and alcohol 
addiction despite its neurotoxic and cardiotoxic properties (Litjens 
and Brunt, 2016), raising concerns about its use in other applica-
tions. The oral LD50 of ibogaine in mice is 263 mg/kg of body 
weight (Kubiliene et al., 2008). Various non-alkaloid phytochemi-
cals present in T. iboga may exert hypoglycemic activities. In ad-
dition, iboga phytochemicals may ameliorate type 2 diabetes by 
non-pancreatic mechanisms, such as preventing weight gain, the 
most important risk factor of the disease, and improving muscle-
dependent insulin resistance (Gonzalez-Castejon et al., 2011). To 
date, there is insufficient scientific information regarding the ap-
propriate range of doses for iboga extract as a remedy for diabetes, 
metabolic syndrome, or even for treatment of opioid drug depend-
ence (Schep et al., 2016).
In traditional medicine, T. iboga, has long been used in the form 
of air-dried root bark or macerated root bark (Goutarel et al., 1993). 
Indigenous people in Gabon ingest preparations of the root bark of 
this plant during religious rituals for its psychoactive properties. 
Iboga preparations or the main alkaloid, ibogaine, are currently 
also used for treating addiction to drugs (morphine, heroin, metha-
done and oxycontin) and opiate withdrawal symptoms (Alper et 
al., 1999). The major mechanism of action of ibogaine appears to 
be its ability to bind to multiple binding sites within the central 
nervous system (CNS), such as N-methyl-D-aspartate (NMDA), 
receptor coupled ion channels, κ-opioid (κ1 and κ2), μ-opioid and 
σ2, serotonin (5-HT2 and 5-HT3), muscarinic (M1 and M2) re-
ceptors, monoamine oxidase receptors, and nicotinic acetylcholine 
receptors (Maciulaitis et al., 2008). Ibogaine activates the glial cell 
line—derived neurotrophic factor (GDNF) pathway in the ventral 
segmental area of the brain (Maciulaitis et al., 2008).
The overall objective of this study was to determine whether di-
etary administration of T. iboga extracts can mitigate hyperglyce-
mia in male C57BL/6J mice, a mouse model that develops obesity, 
hyperglycemia, and glucose intolerance/insulin resistance when 
fed a HFD (Miranda et al., 2016). Using this HFD-induced obese 
mouse model, we have previously shown that oral treatment with 
xanthohumol, a hop flavonoid, for 12 weeks attenuates weight 
gain and decreases fasting plasma levels of glucose, total triglycer-
ides, insulin, leptin, IL-6, and low-density lipoprotein cholesterol 
(LDL-C) in a dose-dependent manner (Miranda et al., 2016). We 
also investigated the effects of iboga extract feeding on cognitive 
performance in the water maze.
2. Experimental design and methods
2.1. Preparation of iboga extract
Root bark of T. iboga was provided by the Institute of Pharma-
copoeia and Traditional Medicine (IPHAMETRA) in Libreville, 
Gabon. Iboga extract for the mouse feeding study was prepared 
by the method of Sadoon et al. (2014). In short, root bark chips 
were ground using a coffee grinder to obtain a fine powder. The 
powder (50 g) was macerated in water with magnetic stirring for 
24 h at room temperature. The slurry was filtered and the residue 
rinsed twice with water. The water extract was adjusted to pH 9 
with ammonium hydroxide and then extracted five times with 
chloroform in the fume hood. Anhydrous sodium sulfate was add-
ed to the combined chloroform extracts and the chloroform layer 
was filtered before drying under vacuum using a rotary evapora-
tor to obtain 4 g of a dry residue. The residue (iboga extract) was 
characterized by liquid chromatography in combination with mass 
spectrometry (LC-MS/MS), using the facilities of the Mass Spec-
trometry Center at Oregon State University, and used for preparing 
the iboga-fortified diet.
2.2. Measurement of ibogaine concentration in iboga bark by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS)
A Shimadzu Prominence HPLC system (Shimadzu, Columbia, 
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MD, USA), consisting of two LC-20AD pumps, a DQU-20A 
degasser, and an SIL-HTC autosampler, was used for chroma-
tography of the iboga extract. The autosampler and column oven 
temperature were maintained at 10 and 40 °C. Chromatographic 
separation of ibogaine was achieved on an Agilent Poroshell 120 
EC-C8 column (2.1 × 50 mm, 2.7 µm) eluted with solvent A (wa-
ter with 0.1% formic acid) and B (acetonitrile with 0.1% formic 
acid). The solvent gradient started at 10% B at 0–0.5 min, changed 
to 24% B at 5.5 min, and then to 100% B at 6 min, to 10% B at 
6.1 min, and then the column was equilibrated with 10% B un-
til 9.1 min. The injection volume was 5 µL and the mobile phase 
flow was 200 µL/min. The column effluent was introduced into 
the electrospray ionization source of an Applied Biosystems 4000 
QTRAP hybrid linear ion trap-triple quadrupole instrument (Sciex, 
Concord, ON, Canada) operated at a source temperature of 400 °C 
with a needle voltage of 5 kV in the positive ion mode. Nitrogen 
was used as the source gas (40 psi) and curtain gas (30 psi). Multi-
ple reaction monitoring (MRM) experiments were conducted with 
the collision energy set at 50 V, the collision cell exit at 9 psi, and 
the de-clustering potential set at 60 V. Ibogaine was detected using 
multiple reaction monitoring, using m/z 311.4 > 174.1 as the quali-
fier transition and m/z 311.4 > 122.1 as the quantifier transition. 
The concentration of ibogaine in the bark extract was determined 
by the external calibration method using a standard of ibogaine 
obtained from Cambridge Chemicals (Woburn, Massachusetts, 
U.S.A.).
2.3. LC-MS detection of other phytochemicals in T. iboga root 
bark
Pieces of iboga root bark were ground to a fine powder by using a 
coffee grinder. Ten milligrams of bark powder were extracted with 
10 mL of 70% aqueous methanol (v/v) by sonication for 30 min 
at 25 °C. After sonication, the extract was centrifuged at 15,000 
rpm for 10 min. Chromatographic separation was conducted us-
ing a Shimadzu Nexera UPLC system equipped with an Inertsil 
Phenyl-3 column (150 × 4.6 mm, 5 µm). The injection volume 
was 10 µl. Mobile phase A was water with 0.1% formic acid, and 
mobile phase B was methanol with 0.1% formic acid. The gradi-
ent started with 5% B and was held for 1 min at 5% B, followed 
by a 10-min linear gradient from 5% to 30% B. The gradient was 
increased linearly to 100% B at 20 min, held for 10 min at 100% 
B and, finally, stepped back to 5% B to equilibrate the column. 
The flow rate was 0.4 mL min−1, with the auto-sampler set at 10 
°C, and the column temperature was maintained at 50 °C. The 
column effluent was introduced into a QToF mass spectrometer 
(AB Sciex Triple TOF 5600) equipped with a TurboSpray elec-
trospray ionization source operated in the negative and positive 
ionization modes. The instrument was operated in the informa-
tion-dependent acquisition (IDA) mode using a collision energy 
of 35 V. For analysis of phenolic compounds, compound identifi-
cation was based on accurate mass, isotopic similarity, retention 
time and MS/MS spectral comparison with authentic compounds. 
A targeted analysis was performed for 1,3-di-O-caffeoylquinic 
acid, 1,5-di-O-caffeoylquinic acid, 3,4-di-O-caffeoylquinic acid, 
3,5-di-O-caffeoylquinic acid, 3-O-caffeoylquinic acid, 4,5-di-O-
caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic 
acid, caffeic acid, catechin, dihydrocaffeic acid, dihydroferulic 
acid, dihydroisoferulic acid, epicatechin, epigallocatechin, feru-
lic acid, isoferulic acid, kaempferol, naringin, quercetin and ru-
tin. An external calibration curve was prepared for all precursor 
ions (Calibration points: 0.05, 0.1, 0.5, 1.0, 5.0 mg L−1, R values 
>0.995).
2.4. Qualitative analysis of iboga extract
For qualitative (untargeted) analysis, LC-MS/MS data were ac-
quired on the AB Sciex Triple TOF 5600 system using the same 
chromatographic separation. In order to detect alkaloids as pro-
tonated molecular species, MS acquisition was performed in the 
positive ionization mode. Raw data were processed by using Pro-
genesis QI software (NonLinear Dynamics, Newcastle upon Tyne, 
UK). Progenesis QI is a bioinformatics tool for small molecule dis-
covery and analysis. Over 6,300 raw mass spectra were collected. 
Metabolites were assigned by extensive querying and comparison 
of molecular features, namely accurate mass (m/z), MS/MS frag-
mentation pattern, and isotopic similarity, against MetlinTM MS/
MS, HMDB (Wishart et al., 2018), KEGG and KnapSack data-
bases. In the Progenesis QI workflow, we considered a confidence 
score higher than 50 sufficient for assignment of constituents in 
the iboga extract. A score higher than 50 for a putative compound 
is reached when the deviation of the accurate mass from the exact 
mass is lower than 5 ppm combined with an isotopic pattern simi-
larity >90%.
2.5. Animal studies
The animal studies were conducted with the approval from the In-
stitutional Animal Care and Use Committee of Oregon State Uni-
versity, Corvallis, Oregon, USA. Animal experiments were carried 
out in accordance with the relevant guidelines and regulations. The 
HFD contained 60%, 20% and 20% total calories from fat, carbo-
hydrate and protein, respectively. This HFD diet has been shown 
to induce obesity and metabolic syndrome in male C57BL/6J mice 
(Miranda et al., 2016). The LFD contained 10%, 70% and 20% 
total calories from fat, carbohydrate and protein, respectively. Both 
diets were obtained from Dyets Inc., Bethlehem, PA, USA. The 
HFD was fortified with iboga extract on a weekly basis by dissolv-
ing a calculated amount of extract in a small volume of ethanol for 
incorporation into the diet, so that it would provide an ibogaine 
dose of 0.83 (low dose) or 2.08 mg/kg body weight per day. To 
obtain a daily dose of 2.08 mg ibogaine/kg body weight, a mouse 
weighing 23.8 g was provided a total dose of 49.5 µg of ibogaine. 
The amount of iboga extract containing 49.5 µg ibogaine was 
dissolved in ethanol and mixed with 2.5 g of diet that the mouse 
would consume per day. The ethanol in the pellets of diet was al-
lowed to evaporate in a fume hood. The fortified amount of iboga 
extract was adjusted each week based on the previous week’s body 
weight and food intake.
Male C57BL/6J mice, 8 weeks of age, were purchased from 
The Jackson Laboratory, Bar Harbor, ME, USA, and maintained 
on a 12 h dark/light cycle and fed a regular mouse chow diet. Af-
ter 1 week of acclimation, the mice were randomly assigned into 
4 groups of 12 animals, namely: Group 1, LFD normal control; 
Group 2, HFD control; Group 3, HFD + low-dose iboga (0.83 mg 
ibogaine/kg body weight/day); and Group 4, HFD + high-dose 
iboga (2.07 mg ibogaine/kg body weight/day). Each mouse was 
housed individually in labeled plastic cages with bottled tap water 
in plastic containers and fed their respective diets ad libitum. Body 
weights were recorded weekly. Food intake was monitored daily 
during the 10-week feeding study.
During the 4th and 9th week of the study, a glucose tolerance 
test (GTT) was performed. Five C57BL/6J mice in each treatment 
group were fasted for 4 h and given an intraperitoneal (i.p.) in-
jection of D-glucose (2 g/kg body weight). A drop of blood was 
collected from a tail prick at 0, 30, 60, 90 and 120 min after the 
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glucose bolus injection for measuring glucose using a Johnson and 
Johnson One Touch® Ultra Blood Glucose Monitoring System. 
An insulin tolerance test (ITT) was also conducted at 9 weeks of 
the feeding study. Another set of five mice in each treatment group 
were fasted for 4 h before giving them an i.p. dose of insulin (0.75 
U/kg body weight). Blood glucose was determined using the same 
protocol as the glucose tolerance test.
At the end of the 10th-week feeding period, all mice, after an 
overnight fast, were euthanized via CO2 inhalation and blood was 
collected for endpoint biomarkers of metabolic syndrome, includ-
ing diabetes. Blood plasma was analyzed for insulin, leptin, and 
inflammatory markers (MCP-1, IL-6, MMP-9 and I-CAM-1) us-
ing ELISA kits. Total plasma cholesterol and triglycerides were 
analyzed using InfinityTM Cholesterol Reagent and InfinityTM 
Triglyceride Reagent kits, respectively (ThermoDMA, Louisville, 
CO). Plasma glucose was analyzed by the Autokit Glucose (Wako 
Chemicals USA, Inc., Richmond, VA). Plasma low-density lipo-
protein cholesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), AST and ALT were estimated by commercially avail-
able kits (Bioo Scientific Corporation, Austin, TX).
2.6. Cognitive function
HFD mice were tested three days before sacrifice for cognitive per-
formance using the water maze as previously described (Miranda 
Figure 1. Influence of diet and iboga extract on glucose tolerance in mice at 4 weeks (a, b) and 9 weeks (c, d) and on insulin tolerance at 9 weeks (e, f) 
of the feeding study. The mice were fasted for 6 h before i.p. injection of glucose, 2 g/kg body weight, or of insulin, 0.75 U/kg body weight, before blood 
glucose was analyzed at designated times. LFD, low-fat diet; HFD, high-fat diet; Ib, ibogaine. Data presented in panels A, C, and E were analyzed using a 
repeated-measures-in-time design ANOVA in PROC MIXED for repeated measures within animals (n = 5 per group). Data presented in panels B, D, and F 
were analyzed using a one-way ANOVA and a post-hoc Tukey’s multiple comparison test. Statistical differences between groups are indicated with different 
letters (a, b, c; p < 0.05).
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et al., 2018). Briefly, the water maze consisted of a large circular 
pool filled with water made opaque with white chalk and surround-
ed by spatial cues. Mice were trained to locate a clear platform (12 
cm diameter) submerged 1 cm below the water surface. During 
visible trials, this target platform was marked with a visible flag. 
Each trial consisted of the animal being placed at the edge of the 
pool and allowed to explore the maze. Drop locations were rotated 
and the platform location was moved to different quadrants of the 
maze after trials 2 and 8 so that procedural memory would not 
be used to find the platform. Trials lasted 60 s or until the mouse 
located the platform and remained on it for 3s. If an animal did not 
locate the platform within 60 s, it was led to the platform by the 
experimenter. During visible trial days, mice underwent 2 trials, 
and during hidden trial days, mice underwent 3 trials. Same-day 
trials were separated by a 10-minute interval.
After hidden training, mice were tested for spatial memory re-
tention in a probe trial, during which the platform was removed 
from the maze completely. To ensure that mice learned the task, 
they were tested in two additional trials to locate a platform con-
taining a visible flag following the probe trial.
Trials were recorded using Ethovision XT 7 software (Noldus 
Information Technologies, Wageningen, The Netherlands). To as-
sess spatial learning and memory, latency to the platform and cu-
mulative distance to the target was analyzed for training. Cumula-
tive distance to the target was also assessed during the probe trials. 
To ensure differences in cognitive performance were not based on 
differences in swim speed, mean swim speed during each trial type 
was analyzed.
2.7. Statistical analysis
Data were analyzed using SAS 9.2 software (SAS Institute Inc., 
Cary, NC) and GraphPad Prism 5.0 (San Diego, CA). Body 
weight, food intake, GTT, and ITT data were analyzed using a 
repeated-measures-in-time design ANOVA in PROC MIXED. 
Repeated measures within animals were modeled using a first-
order autoregressive variance-covariance structure (body weight 
and food intake) or an unstructured variance-covariance structure 
(GTT and ITT data. Baseline values were used as linear covariate 
for body weight and feed intake data. The AUC data presented in 
Figure 1 were analyzed using a one-way ANOVA and a post-hoc 
Tukey’s multiple comparison test. A p-value <0.05 was consid-
ered statistically significant. For the water maze learning curve, the 
data were analyzed using repeated measures ANOVA with SPSS 
software (v.25, Chicago, IL). If Mauchly’s test of Sphericity was 
significant (p < 0.05) and sphericity therefore violated, the Green-
house-Geisser correction was used. GraphPad Prism was used for 
data visualization.
3. Results and discussion
3.1. Estimation of ibogaine and total alkaloid concentration in 
iboga extract
Figure 2 shows the chromatograms of the ibogaine standard and 
ibogaine in the bark extract. The powdered root bark of iboga con-
tained 1.93% ibogaine (w/w). The chromatographic peak area of 
ibogaine comprised 24.6% of the total area of chromatographic 
peaks assigned to known and unknown alkaloids based on their 
common mass defect. Therefore, we estimated that the total alkaloid 
content of the bark amounts to 7.8%. This number is higher than 
the 5–6% indole alkaloids in the root bark reported by Delourme-
Houdé (1946), Marion (1952) and Dewick (2002) but lower than 
the alkaloid content of powdered iboga root (7.2% ibogaine, 0.6% 
ibogamine) reported by Mazoyer et al. (2013). Only seven alkaloids 
have been reported for T. iboga previously (Table 1), all of which 
we identified by our plant metabolomics approach. In addition, we 
tentatively assigned 23 other alkaloids reported for other plant spe-
cies, including taxa belonging to the Apocynaceae (Table 1).
3.2. Rationale for the selection of the dose
We used the calculated ibogaine content of 1.93% in the bark to 
fortify the diets with iboga extract. The fortified diets delivered 
Figure 2. LC-MS/MS chromatograms of ibogaine.  (a) 10 nM Ibogaine standard. (b) Ibogaine in root bark extract. Multiple reaction monitoring (MRM) transi-
tions: m/z 311.4 > 174.1 (qualifier MRM, c), m/z 311.4 > 122.1 (quantifier MRM, c).
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Table 1.  Phytochemicals detected in T. iboga root bark Compounds detected in the positive electrospray ionization (ESI) mode were assigned using 
Progenesis QI (score >50). For compounds detected by negative ESI-MS, identity was assigned based on comparison of m/z, retention time and MS/MS 
spectra comparison with authentic standards
Alkaloids, positive ESI m/z R.T (min) Detected Adducts Formula Composition %a
Ibogaine1–3 311.2115 21.63 [M+H]+ C20H26N2O 24.60
Iboxygaine4 327.2063 21.46 [M+H]+ C20H26N2O2 11.00
Ibogaline4 341.2220 21.39 [M+H]+ C21H28N2O2 10.77
Alloibogaine 325.1908 22.01 [M+H]+ C20H24N2O2 8.21
Catharanthine4 337.1912 22.77 [M+H]+ C21H24N2O2 5.69
Ibogamine1–3 281.2010 21.58 [M+H]+ C19H24N2 3.37
Noribogaine 297.1958 20.66 [M+H]+ C19H24N2O 2.76
Voacangine1–3 369.2167 21.82 [M+H]+ C22H28N2O3 1.87
Yohimbine 355.2013 19.89 [M+H]+ C21H26N2O3 1.81
Hydroxyibogamine (isomer of noribogaine) 297.1958 21.41 [M+H]+ C19H24N2O 1.79
Quinidine 325.1912 18.64 [M+H]+ C20H24N2O2 1.01
Coronaridine1–3 339.2054 22.86 [M+H]+ C21H26N2O2 0.97
11-O-Demethyl-17-O-deacetylvindoline 383.1965 18.18 [M+H-H2O]
+ C22H28N2O5 0.86
Affinisine 309.1959 20.47 [M+H]+ C20H24N2O 0.84
17-O-Acetylnorajmaline 355.2015 23.68 [M+H]+ C21H26N2O3 0.55
Affinine 325.1908 23.55 [M+H]+ C20H24N2O2 0.43
Rhazidigenine N-oxide 315.2063 19.49 [M+H]+ C19H26N2O2 0.40
1,2-Dihydrovomilenine 353.1858 23.95 [M+H]+ C21H24N2O3 0.23
11-Hydroxyyohimbine 371.1958 20.03 [M+H]+ C21H26N2O4 0.20
16-Methoxytabersonine 367.2010 22.43 [M+H]+ C22H26N2O3 0.19
N4-Demethylechitamine 371.1959 21.72 [M+H]+ C21H26N2O4 0.19
Quinine-N-Oxide 341.1855 19.42 [M+H]+ C20H24N2O3 0.18
Iboluteine 327.2052 23.21 [M+H]+ C20H26N2O2 0.08
Strictosidine aglycone 369.1808 22.68 [M+H]+ C21H24N2O4 0.08
Aspidodasycarpine 353.1859 23.54 [M+H-H2O]
+ C21H26N2O4 0.05
Reserpic acid 401.2069 20.48 [M+H]+ C22H28N2O5 0.03
Ajmaline 327.2061 29.40 [M+H]+ C20H26N2O2 0.02
Jerantinine B 399.1909 19.11 [M+H]+ C22H26N2O5 0.02
Vinervine 321.1596 24.46 [M+H-H2O]
+ C20H22N2O3 0.01
Ellipticine 247.1222 25.46 [M+H]+ C17H14N2 0.01
Unknown alkaloids (48)b N/A N/A [M+H]+ N/A 21.77
Polyphenols and other compounds, positive ESI
4-Guanidinobutanoic acid 146.0918 6.13 [M+H]+ C5H11N3O2 N/A
Betaine 118.0859 4.52 [M+H]+ C5H11NO2 N/A
Catechin 291.0859 13.76 [M+H]+, M+Na]+ C15H14O6 N/A
Choline 104.1071 6.48 [M]+ C5H14NO
+ N/A
Epicatechin 291.0861 15.97 [M+H]+, [M+Na]+ C15H14O6 N/A
Glutamate 148.0599 4.59 [M+H]+ C5H9NO4 N/A
Indoleacetaldehyde 177.1015 10.27 [M+H] C10H9NO N/A
Phosphocholine 184.0728 5.29 [M+H]+ C5H14NO4P N/A
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a daily ibogaine dose of 0.83 and 2.07 mg/kg body weight. The 
mouse doses of 0.83 and 2.07 mg/kg body weight are equivalent to 
human doses of 4.7 mg/day and 12 mg/day for a 70-kg person by 
allometric scaling of dose (Sharma and McNeill, 2009). Assuming 
that the total alkaloid content of the root bark is 7.8% (see previ-
ous paragraph), the human equivalent dose of 12 mg ibogaine per 
day would represent a total alkaloid dose of 49 mg per day (0.70 
mg/kg/day for a 70-kg person) when given in the form of iboga 
bark extract. The selected high dose in our study approaches the 
recently recommended human dose of 0.87 mg ibogaine/kg that is 
considered safe and appropriate for treatment of opioid addiction 
in humans (Schep et al., 2016). Forsyth et al. (2016) investigated 
the effects of a single oral dose of 20 mg ibogaine in humans on 
a number of psychological variables. A pharmaceutical prepara-
tion of T. manii (Lambarène), containing 8 mg ibogaine per tablet, 
was marketed in France as a neuromuscular stimulant, promotor of 
cell combustion, and anti-fatigue agent. The recommended dose 
was 16–32 mg ibogaine per day (2–4 tablets daily) (Goutarel et 
al., 1993). Assuming other iboga alkaloids exert pharmacological 
activity, these doses are comparable to our low dose in mice (hu-
man equivalent dose for a 70-kg person: 20 mg total iboga alka-
loids). As this is the first study designed to investigate the effects of 
iboga phytochemicals in an in vivo model of glucose intolerance, 
we were unable to predict efficacious dose levels for ameliorating 
glucose intolerance.
3.3. Analysis of iboga extract by mass spectrometry
Analysis of over 6,300 mass spectra recorded in the positive ioni-
zation mode revealed 38 compound identifications with high con-
fidence using Progenesis QI (score >50, Table 1). Among them, 
30 compounds are alkaloids previously reported in plants (Afendi 
et al., 2012; Kanehisa et al., 2017; Smith et al., 2005) (MetlinTM, 
HMDB, KEGG or KnapSack, Table 1), with ibogaine as the major 
alkaloid (Figure 3a–c). Further analysis of a 70% aqueous metha-
nol extract by negative ion mass spectrometry using several stand-
ards showed the presence of five phenolic compounds, including 
3-O-caffeoylquinic acid (Table 1, Figure 4). The calculated amount 
of this compound was 0.97 mg/g of the root bark.
3.4. Mass defect analysis
T. iboga root bark is rich in indole alkaloids (Bartlett et al., 1958). 
Alkaloids are particularly suitable for LC-MS analysis in positive 
ionization mode due to the presence of nitrogen atoms with high 
proton affinity. Filtering of data based on mass defect, defined as 
Table 1.  Phytochemicals detected in T. iboga root bark Compounds detected in the positive electrospray ionization (ESI) mode were assigned using 
Progenesis QI (score >50). For compounds detected by negative ESI-MS, identity was assigned based on comparison of m/z, retention time and MS/MS 
spectra comparison with authentic standards - (continued)
Alkaloids, positive ESI m/z R.T (min) Detected Adducts Formula Composition %a
Phenolic compounds, negative ESI
5-O-Caffeoylquinic acid 353.0461 11.86 [M-H]− C16H18O9 <LOQc
1,3-Di-O-caffeoylquinic acid 515.1217 N/A [M-H]− C25H24O12 <LODd
1,5-Di-O-caffeoylquinic acid 515.1210 N/A [M-H]− C25H24O12 <LOD
3,4-Di-O-caffeoylquinic acid 515.1207 N/A [M-H]− C25H24O12 <LOD
3,5-Di-O-caffeoylquinic acid 515.1208 N/A [M-H]− C25H24O12 <LOD
3-O-Caffeoylquinic acid 353.0409 15.28 [M-H]− C16H18O9 0.97±.015 mg/g bark
4,5-Di-O-caffeoylquinic acid 515.1210 N/A [M-H]− C25H24O12 <LOD
4-O-Caffeoylquinic acid 353.0508 N/A [M-H]− C16H18O9 <LOD
Caffeic acid 179.0346 N/A [M-H]− C9H8O4 <LOD
Catechin 289.0729 N/A [M-H]− C15H14O6 <LOD
Dihydrocaffeic acid 181.0497 N/A [M-H]− C9H10O4 <LOD
Dihydroferulic acid 195.0651 N/A [M-H]− C27H30O16 <LOD
Epicatechin 289.0707 N/A [M-H]− C15H14O6 <LOD
Epigallocatechin 305.0668 N/A [M-H]− C15H14O7 <LOD
Ferulic acid 193.0497 19.6 [M-H]− C10H10O4 <LOQ
Isoferulic acid 193.0499 N/A [M-H]− C10H10O4 <LOD
Kaempferol 285.0405 21.95 [M-H]− C15H10O6 <LOQ
Naringin 579.1718 N/A [M-H]− C27H32O14 <LOD
Quercetin 301.0345 21.08 [M-H]− C15H10O7 <LOQ
Rutin 609.1502 19.01 [M-H]− C27H30O16 <LOQ
aAssuming comparable detector responses for detected alkaloids, all which contain two nitrogen atoms indicative of indole alkaloids. bCompounds with a mass defect ranging from 
0.1939 to 0.2100. cLOQ Calibration quantification limit evaluated as S/N ratio 10:1; LOQ > 3.3 µg L−1. dLOD- Calibration detection limit evaluated as S/N ratio 3:1; LOD > 1.0 µg L−1. 
<LOD not detected; <LOQ detected below LOQ. References: 1Afendi et al., 2012; 2Bartlett et al., 1958; 3Harborne et al., 1999; 4Taylor et al., 1968.
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Figure 3. LC-HRMS/MS analysis of iboga extract in positive ionization mode (1 mg mL−1 of dry mass resuspended in 70% aqueous methanol).  (a) Mo-
lecular features detected in iboga extract with a mass defect in a range from 0.1900 to 0.2190. The size of the circles corresponds to the magnitude of the 
chromatographic peak area of a particular feature; the largest circle represents ibogaine. (b) [M+H]+ extracted ion chromatograms (XIC) of indole alkaloids. 
(c) Fragmentation spectrum and proposed dissociation of ibogaine. Data are in accord with those reported by Kontrimaviciute et al.  (2006).
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the difference between the nominal mass and the monoisotopic 
mass of a molecule, referred to as mass defect filtering, is a use-
ful post-acquisition data processing technique to detect groups of 
molecules with similar elemental compositions, such as indole al-
kaloids (Xie et al., 2012). To screen for T. iboga alkaloids, we used 
as reference the mass defect range obtained from the monoisotopic 
neutral mass of reported alkaloids in T. iboga (Afendi et al., 2012; 
Bartlett et al., 1958; Harborne et al., 1999). The absolute mass de-
fect (i.e., mass excess) varied from 0.1939 to 0.2100. The accurate 
mass achieved in this experiment was 5 ppm or better, therefore, 
we used a screening range from 0.1900 to 0.2190 (Figure 3a). Us-
ing this approach, 30 known alkaloids and 48 unknown alkaloids 
were detected (Table 1).
3.5. Effect of diet and iboga extract on body weight, food 
intake and liver weight
The LFD-fed mice gained significantly less weight than the mice 
fed the HFD with or without iboga extract (Figure 5a). The LFD 
mice lost weight during the first week on the LFD and then slowly 
gained weight until the end of the study. The LFD mice actually 
were eating more food than the mice fed the HFD (Figure 5b) but 
their feed efficiency was lower compared to the mice on the HFD 
(Table 2). The HFD mice treated with the low dose of iboga extract 
gained slightly more weight than the HFD mice and the HFD mice 
treated with the high iboga dose. Liver weights were much higher 
in the HFD-fed mice than the LFD-fed mice (Table 2).
3.6. Effect of diet and iboga extract on glucose tolerance and 
insulin sensitivity
One of the major aims of this study was to determine whether in-
Figure 5. Effect of the HFD and iboga extract feeding on body weight 
(a) and food intake (b) of mice. LFD, low-fat diet; HFD, high-fat diet; Ib, 
Ibogaine. Data were analyzed using a repeated-measures-in-time design 
ANOVA in PROC MIXED for repeated measures within animals (n = 12 per 
group). Statistical differences between groups are indicated with different 
letters (a, b, c; p < 0.05).
Figure 4. LC-HRMS/MS analysis of T. iboga root bark extract. (a) Extracted 
ion chromatogram [M–H]−m/z 353.09, 10 µL injection. Black line- 1 mg 
L−1 of standards 3-O-caffeoylquinic acid (3-O-CQA) and 4-O-caffeoylquinic 
acid (4-O-CQA). Blue line- 1 mg ml−1 of bark extract, both resuspended in 
70% aqueous methanol. (b) Fragmentation spectrum of 3-O-CQA detected 
in iboga extract. C. Fragmentation spectrum of 3-O-CQA standard (1mg 
L−1).
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gestion of iboga extract has any beneficial effect on type 2 diabetes 
induced by feeding a HFD. The results of the glucose tolerance 
tests conducted at 4 and 9 weeks of feeding showed that mice fed 
the HFD cleared glucose slower after the glucose bolus dose com-
pared to the LFD group (Figure 1). Oral iboga administration did 
not improve the glucose tolerance of the HFD mice. In fact, the 
HFD mice treated with the low or high iboga dose were slightly 
less glucose tolerant than the HFD controls at 4 weeks of treat-
ment (Figure 1a). Similar results were obtained in the insulin toler-
ance test (Figure 1e, f) in that the HFD-fed mice had higher blood 
glucose levels after insulin injection while iboga exposure did not 
improve the insulin sensitivity of the mice fed a HFD. Therefore, 
our data do not support the conclusions reached by Souza et al. 
(2011) that aqueous extracts of iboga root bark contains anti-hyper-
glycemic natural products for treatment of type 2 diabetes. Using 
isolated islets of Langerhans from the pancreas of non-fasting fe-
male Wistar rats, these authors found that bioactives in the aqueous 
extract of iboga exerted an insulinotropic effect ex vivo, similar but 
not identical in mechanism compared to tolbutamide, a representa-
tive of the sulfonylurea class of type 2 diabetic drugs. With chronic 
administration of sulfonylureas, insulin levels do not change with 
treatment, consistent with our observations, but fasting plasma glu-
cose levels decrease due to lowering of insulin resistance (Davis, 
2006), which we did not observe with iboga treatment. One expla-
nation for the discrepancy is that the doses used in our study were 
not optimal. In addition, we cannot exclude the possibility that 
iboga bioactives are converted into inactive metabolites by gut mi-
crobial or hepatic metabolism. For instance, ibogaine undergoes O-
demethylation by the hepatic cytochrome P450 enzyme CYP2D9 
(Obach et al., 1998). It is possible that the metabolite, 12-hydroxyi-
bogamine (syn. noribogaine), lacks insulinotropic activity.
The amount of 3-O-caffeoylquinic acid in iboga root bark, ex-
tracted with 70% aqueous methanol, was determined to be 0.97 
mg/g. 3-O-caffeoylquinic acid is a commonly found food bioac-
tive with anti-tumor, antioxidant and anti-inflammatory activities 
(Jabeur et al., 2016). Oral administration of 3-O-caffeoylquinic 
acid (syn. chlorogenic acid) to HFD-fed C57BL/6J mice at 100 
mg/kg body weight per day resulted in increased insulin resist-
ance and hepatic lipid accumulation compared to the HFD control 
mice (Mubarak et al., 2013). By contrast, when HFD-fed ICR mice 
were treated orally with chlorogenic acid at a dose of 20 mg/kg 
body weight per day, their insulin levels decreased indicative of 
improvement of insulin sensitivity (Cho et al., 2010). In our study, 
the high iboga dose corresponded to an intake of about 107 mg 
bark/kg body weight per day, which would have provided a 3-O-
caffeoylquinic acid dose of 0.10 mg/kg body weight per day if 
the extraction yield were quantitative. Therefore, a 70% aqueous 
methanol extract of iboga root bark at a daily dose of 107 mg bark/
kg body weight would not have affected the HFD-induced insulin 
resistance due to the low dose of 3-O-caffeoylquinic acid. To test 
the hypothesis that the alkaloids in iboga root bark, and not 3-O-
caffeoylquinic acid, are in fact responsible for the reported bio-
logical effects, we prepared an alkaloid extract devoid of phenolic 
acids for testing in the mice in this study.
3.7. Effect of diet and iboga extract on other metabolic param-
eters
One major concern of the use of herbal or dietary supplements 
such as kava-kava (Stickel and Shouval, 2015) is liver damage. 
Plasma levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) are generally used as indicators of liver 
injury (Ozer et al., 2008). As shown in Table 2, no significant dif-
ference was observed in ALT and AST between LFD-fed mice and 
HFD-fed mice. Supplementation of the HFD with iboga extract did 
Table 2.  Body weight gain, food intake, liver weight and metabolic parameters of mice fed experimental diets
Parameter LFD HFD HFD + Low Ib HFD + High Ib
Body weight gain (g) 0.33 ± 0.00 8.96 ± 0.72* 11.6 ± 0.71* 8.86 ± 0.67*
Food intake (g/day) 2.74 ± 0.04 2.45 ± 0.04* 2.48 ± 0.04* 2.48 ± 0.04*
Feed efficiency (g weight gain/g food intake) 0.002 ± 0.000 0.052 ± 0.003* 0.067 ± 0.003* 0.051 ± 0.003*
Liver weight (g) 0.834 ± 0.042 1.31 ± 0.196* 1.23 ± 0.044* 1.09 ± 0.042*
Plasma glucose (mg/dL) 243 ± 24.9 310 ± 24.4* 343 ± 12.4* 284 ± 24.1*
Plasma triglycerides (mg/dL) 48.8 ± 1.89 60.6 ± 4.56* 64.9 ± 4.57* 66.6 ± 5.17*
Plasma cholesterol (mg/dL) 170 ± 8.96 256 ± 8.18* 258 ± 8.96* 231 ± 14.0*
Plasma LDL-C (mg/dL) 43.9 ± 6.95 88.7 ± 13.6* 80.8 ± 7.82* 80.6 ± 7.17*
Plasma HDL-C (mg/dL) 54.7 ± 7.29 72.4 ± 3.36* 72.9 ± 1.99* 74.1 ± 3.37*
Plasma insulin (ng/mL) ND 1.35 ± 0.23 1.21 ± 0.16 1.33 ± 0.33
Plasma leptin (ng/mL) 6.18 ± 1.67 26.1 ± 2.26* 30.8 ± 1.31* 26.8 ± 1.81*
Plasma IL-6 (pg/mL) 6.98 ± 0.46 9.96 ± 1.17* 8.55 ± 0.65* 8.75 ± 0.05*
Plasma ICAM-1(ng/mL) 17.7 ± 3.48 34.3 ± 2.34* 33.8 ± 1.87* 34.1 ± 1.97*
Plasma MCP-1 (pg/mL) 134 ± 8.09 810 ± 284.2* 81.5 ± 23.6** 337 ± 119
Plasma MMP-9 (ng/mL) 30.9 ± 8.09 45.6 ± 13.8 57.8 ± 14.3 30.6 ± 5.72
Plasma ALT (U/L) 50.2 ± 3.92 48.2 ± 1.92 54.7 ± 7.0 45.2 ± 3.79
Plasma AST (U/L) 156 ± 12.9 147 ± 8.81 118 ± 13.8 131 ± 21.2
All values are means ± SE of 11–12 animals. * p < 0.05 versus LFD. ** p < 0.05 versus HFD.
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not cause a significant increase in ALT or AST suggesting that the 
extract is not hepatotoxic.
The results listed in Table 2 showed that mice fed a HFD had 
significantly higher plasma levels of glucose, triglycerides, LDL-
cholesterol, HDL-cholesterol, leptin IL-6, ICAM-1, and MCP-1 
compared to the group fed LFD. The addition of iboga extract to 
the HFD did not have a significant effect on any of these meta-
bolic parameters, except for the reduction of plasma levels of 
MCP-1 by low-dose iboga treatment (Table 2). MCP-1 or CCL2 
is a chemokine that may contribute to low-grade inflammation in 
obesity by recruiting monocytes to adipose tissues (O’Connor et 
al., 2015). Therefore, iboga bioactives may be beneficial in ame-
liorating low-grade inflammation in obesity.
3.8. Cognitive performance
We tested HFD mice in the water maze to assess the effects of 
iboga on spatial learning and memory (Figure 6). Mice were first 
trained with a visual flag for 1 day followed by 2 days of hidden 
training. On the 4th day, mice were tested for spatial memory re-
tention during a probe trial, which was followed by 2 additional 
visual trials.
Analysis of visual trials showed that mice learned the task 
and swam closer to the target with additional trials (Figure 6a–d. 
Mauchly’s sphericity test: p = 0.005; One-Way RM ANOVA with 
Greenhouse-Geisser correction: F(3, 76.55) = 40.473, p < 0.001). 
There were no significant differences due to group treatment. Hid-
den trials analysis shows that there was an overall improvement 
(One-Way RM ANOVA: F(5, 160) = 6.75, p < 0.001). Interest-
ingly, this effect was absent in the high dose iboga group (Figure 
6c. p = 0.55), but the control and low dose iboga group showed sig-
nificant improvement (Figure 6a and b. F(5, 55) = 5.2, p = 0.001; 
F(5, 55) = 2.51, p = 0.040).
Probe trial analysis showed significant differences due to iboga 
treatment (Figure 6e. One-Way ANOVA: F(2, 33) = 3.346, p = 
0.048). This was driven by a difference between the control mice 
and high dose iboga group indicating that the mice in the high 
dose iboga group swam on average further away from the location 
where the hidden platform was located during training (Dunnett’s 
post hoc test: p = 0.039), indicating a memory retention impair-
ment.
Figure 6. Cognitive performance of HFD mice in the water maze. High dose iboga-treated mice show impaired spatial learning and memory. (a) HFD control 
mice show improved performance during both the hidden and visible sessions demonstrated by decreasing cumulative distance to the target (One-Way 
ANOVA, F(5,55) = 5.20, p = 0.001). (b) HFD low dose iboga mice show improved performance during both the hidden and visible sessions demonstrated by 
decreasing cumulative distance to the target (one-way ANOVA, F(5,55) = 2.51, p = 0.040). (c) HFD high dose iboga mice fail to show improved performance 
during the hidden sessions (One-Way ANOVA, p = 0.55). (d) Cumulative distance to the target during training sessions shown for all high fat diet groups. (e) 
During the probe trial (occurring prior to trial 9), HFD high dose iboga mice did more poorly and swam further away from the target location than HFD mice 
not receiving iboga (Dunnett’s post hoc test: p = 0.039). (f) There were no differences in swim speed between the groups. Mice generally swam faster during 
the probe trial. (One-Way RM ANOVA, F(2, 66) = 5.37, p = 0.007).
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Although HFD mice weighed more, water maze differences 
were not due to group differences in the swim speed. Mice did, 
however, generally swim faster during the probe trial than during 
visible and hidden platform trials (Figure 6f. One-Way RM ANO-
VA: F(2, 66) = 5.37, p = 0.007).
As a whole, the results of the water maze trial indicate that high 
dose iboga treatment may be harmful and impair spatial learning 
and memory. These data are consistent with the lack of beneficial 
effects of iboga on psychological performance beyond perhaps im-
proving selective attention (Forsyth et al., 2016).
4. Conclusion
By using high-resolution accurate mass spectrometry in combina-
tion with database searching, we tentatively identified 30 indole 
alkaloids in the bark extract of T. iboga, seven of which have been 
reported previously as constituents of T. iboga. Feeding a HFD to 
male mice for 10 weeks resulted in obesity and high plasma levels 
of circulating glucose and insulin, which were not attenuated by 
treatment with iboga extract at dose levels of 0.83 and 2.07 mg/kg/
day. However, plasma levels of MCP-1, a chemokine involved in 
inflammation in obesity, was significantly attenuated by low-dose 
iboga extract (0.83 mg/kg/day) suggesting an anti-inflammatory 
effect of the extract. The results of the water maze study indicate 
that bioactives found in Iboga extract may impair spatial learning 
and memory.
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